Meng et al. previously found that women with serous ovarian cancer and ascites specimens with higher expression of the CSC marker CD44 had significantly poorer progression-free survival (6 vs. 18 mos, P = 0.01) [26]. The gene discussed is CD44; the disease is ovarian serous adenocarcinoma.